Blood transfusion nursing: a guide for nursing students

Blood transfusion nursing is among the highest-stakes procedural skills in clinical practice. From verifying the right unit reaches the right patient, to catching a febrile reaction within the first 15 minutes, every step in the transfusion process carries direct life-or-death implications. NCLEX tests this content extensively because most serious transfusion errors trace back to preventable identification and process failures at the bedside.

This guide covers every NCLEX-tested element: blood product types, pre-transfusion verification, IV access requirements, monitoring schedules, transfusion reactions in detail, the universal “stop the transfusion” protocol, massive transfusion, and documentation requirements.

Blood product types

Understanding what each product contains, why it is ordered, and how it must be handled is the foundation of safe transfusion practice.

Blood product	Primary indication	Usual adult dose	Storage temperature	Maximum infusion time	Special considerations
Packed red blood cells (PRBCs)	Symptomatic anemia, acute blood loss. AABB 2023: consider transfusion at Hgb <7 g/dL in stable inpatients; 7.5 g/dL in cardiac surgery; 8 g/dL in orthopedic surgery or preexisting cardiovascular disease	1 unit (~250–350 mL); expect Hgb rise of ~1 g/dL per unit	1–6°C (refrigerated)	4 hours from issue	20–24G for routine adult transfusion, 14–18G for rapid transfusion (INS 2024); Y-tubing with 0.9% NS only; never dextrose or LR
Platelets	Thrombocytopenia with active bleeding, prophylaxis, or before procedures. AABB/ICTMG 2025 thresholds: prophylactic <10,000 (chemotherapy or allogeneic transplant), CVC placement <10,000, lumbar puncture <20,000, major surgery <50,000	1 apheresis unit or 4–6 pooled random-donor units	20–24°C (room temp, agitated continuously)	Usually 30–60 minutes per dose; complete within 4 hours	Cannot refrigerate – cold activates platelets causing clumping. ABO compatible preferred but not always required. CMV-negative/irradiated for immunocompromised patients.
Fresh frozen plasma (FFP)	Coagulopathy (DIC, liver failure, warfarin reversal, massive transfusion), factor deficiencies when specific factor concentrate unavailable	10–15 mL/kg (typically 2–4 units)	−18°C or colder (frozen); thawed at 37°C before infusion	Complete within 4 hours of issue. Thawed FFP can be stored at 1–6°C for up to 24 hours (relabeled thawed plasma up to 5 days)	Must be ABO compatible (contains plasma antibodies). Contains all clotting factors. Used in DIC and massive transfusion protocol (MTP). See the [DIC nursing guide](/nursing-tips/dic-nursing/) for coagulopathy management.
Cryoprecipitate	Fibrinogen deficiency (<100–150 mg/dL), von Willebrand disease, hemophilia A (when factor VIII concentrate unavailable), DIC	About 1 unit per 10 kg (often a pool of 5–10 units); a pool of 5–6 units raises fibrinogen by about 50 mg/dL	−18°C or colder (frozen); thawed at 37°C	4 hours once thawed; infuse rapidly (15–30 min)	Contains fibrinogen, factor VIII, factor XIII, vWF, fibronectin. Does NOT contain factor IX – not for hemophilia B. See [hemophilia nursing](/nursing-tips/hemophilia-nursing/) for factor replacement context.

Red cell thresholds: The AABB 2023 restrictive thresholds apply to hemodynamically stable patients, not to active hemorrhage. Acute myocardial infarction is a gray zone: the MINT trial (2023) found that a liberal threshold below 10 g/dL did not significantly reduce death or recurrent MI compared with a restrictive 7–8 g/dL threshold, though the results trended toward benefit, so cardiology teams often individualize.

Key distinction for NCLEX: Platelets are stored at room temperature with continuous gentle agitation – refrigerating them destroys function. PRBCs are refrigerated. FFP and cryoprecipitate are frozen and must be thawed before use.

Pre-transfusion verification

The verification process is where most transfusion errors are preventable. Every step exists for a reason – a wrong-unit transfusion causes an acute hemolytic reaction that can kill within minutes.

Type and screen vs. crossmatch

Type and screen (T&S): Determines the patient’s ABO/Rh blood group and screens for unexpected alloantibodies in serum. Required before any non-emergency transfusion. If the patient has been transfused or pregnant in the past 3 months, or the history is unknown, AABB Standards require the sample to be collected within 3 days of the transfusion, because new antibodies can form quickly after exposure. For patients without recent transfusion or pregnancy, many blood banks accept an older sample (often up to 7–14 days) per facility policy.

Crossmatch: Takes the patient’s serum and mixes it directly with the donor unit’s red cells to detect incompatibility. An immediate spin crossmatch takes 5–10 minutes. A full serological crossmatch takes 45–60 minutes and is required when the antibody screen is positive.

Emergency release: In hemorrhagic shock when there is no time for crossmatch, O-negative uncrossmatched blood is released immediately. O-negative is the universal donor for red cells (no A, B, or Rh antigens). Once the patient’s type is known, type-specific blood is issued.

Bedside verification (the critical safety step)

Before hanging any blood product, the patient and the unit must be matched at the bedside. The Joint Commission requires either a two-person verification (the qualified transfusionist who will give the blood plus a second person the hospital deems qualified, often a second RN) or a one-person verification with automated identification technology such as bar-code scanning. Your facility policy sets which method you use. Check each of the following:

Patient name matches exactly (ask patient to state name; do not read it to them)
Patient date of birth matches
Medical record number matches
Blood type and Rh factor on unit matches patient’s type
Crossmatch compatibility tag is attached and shows compatible
Unit number on the bag matches the compatibility form
Expiration date/time has not passed
Blood bag integrity: no visible clots, unusual color, leaks, or bubbling

If any element does not match: do not hang the unit. Return it to the blood bank and clarify. This is non-negotiable.

Document that the patient (or surrogate) has provided informed consent for transfusion before the process begins. Jehovah’s Witness patients and other patients with religious or personal objections must have documented refusal and a care plan established with the provider.

IV access requirements

Catheter gauge: The INS 2024 standards support a 20–24G peripheral catheter for routine transfusion, chosen by vein size, and a larger 14–18G catheter when rapid transfusion is needed. Many hospitals still prefer 18–20G in adults. Hemolysis through small catheters is mainly a risk with high pressure or rapid rates, so avoid pressure bags on a small catheter. In neonates and children, 22–24G catheters are routine.

Central lines: A central venous catheter (CVC) or PICC line can be used for blood products. Confirm patency with a saline flush first. Do not use a luminal port that is running a vasoactive medication or TPN simultaneously – dedicate a lumen.

Tubing requirements:

Use Y-type blood tubing with an in-line 170–260 micron filter (standard). The filter removes clots and microaggregates.
Prime with 0.9% normal saline only. Dextrose solutions (D5W) cause hemolysis by creating a hypotonic environment. Lactated Ringer’s (LR) contains calcium, which overwhelms the citrate anticoagulant (citrate works by binding calcium) and can trigger clotting in the tubing. AABB Standards allow only 0.9% sodium chloride unless another solution is FDA-approved or documented safe for that purpose.
Change the blood administration set and filter after each unit or every 4 hours (INS), or as the manufacturer and your facility policy specify.
Never add medications to blood products or run medications in the same line concurrently.

For IV access technique, see the IV insertion nursing guide.

Transfusion initiation and monitoring

Starting the transfusion

Obtain baseline vital signs (temperature, blood pressure, heart rate, respiratory rate, SpO2) immediately before hanging the unit.
Start the transfusion slowly: about 1–2 mL/min (60–120 mL/hr) for the first 15 minutes, or the rate in your facility policy (Bloodworks Northwest uses 100 mL/hr for adults). This slow start allows early detection of severe reactions before a large volume is infused.
Stay at the bedside for the entire first 15 minutes. The most dangerous reactions (acute hemolytic, anaphylactic) occur within minutes of starting. You cannot catch them from the nursing station.
After 15 minutes, if no reaction: increase rate as ordered. A typical adult unit of PRBCs infuses over 1.5–4 hours. Each unit must be completed within 4 hours. Most facilities count the 4 hours from when the unit leaves the blood bank (issue) or controlled storage, rather than from the spike (the BSH 2018 guideline uses removal from controlled storage), so start promptly after pickup and follow your blood bank’s policy.

Vital signs schedule

Time point	Action
Before transfusion starts	Baseline VS
15 minutes after start	VS check – most critical window
30 minutes after start	VS check
1 hour after start	VS check (intervals after the first 15 minutes vary by facility policy)
End of transfusion	Final VS
Any symptom change	Immediate VS + assessment

Temperature is the key vital sign. NHSN defines transfusion fever as ≥38°C (100.4°F) with a rise of at least 1°C (1.8°F) from the pre-transfusion value. Chills, flushing, back pain, or dyspnea at any point mean stop the transfusion immediately and assess.

Transfusion reactions

Transfusion reactions are the most heavily NCLEX-tested content in this topic. You need to know each type’s mechanism, onset, presentation, and nursing response – including which reactions allow you to restart the transfusion and which do not.

Reaction type	Onset	Key symptoms	Mechanism	Nursing action	Can restart?
Febrile non-hemolytic (FNHTR)	During or within 4 hours after the transfusion (NHSN)	Fever ≥1°C rise, chills, rigors, headache. No hemolysis. BP stable.	Recipient antibodies react against donor leukocyte antigens. Cytokine accumulation in stored blood also contributes.	Stop transfusion. Notify provider. Administer acetaminophen (not aspirin). Reassess. Because fever is also the first sign of AHTR and bacterial contamination, many facilities do not restart the implicated unit. Restart only on provider order after hemolysis and sepsis have been excluded.	Rarely – only per provider and blood bank policy, after hemolysis and bacterial contamination are excluded
Acute hemolytic (AHTR)	Usually within minutes, after just a few mL; NHSN counts reactions up to 24 hours after the transfusion	Fever, chills, severe back/flank pain, dark red/brown urine (hemoglobinuria), hypotension, tachycardia, sense of impending doom. DIC can develop.	ABO incompatibility – patient's antibodies (anti-A, anti-B) activate complement and destroy donor RBCs intravascularly. Most often due to clerical/identification error.	STOP transfusion immediately. Disconnect blood tubing at patient – do not flush blood into patient. Keep IV patent with NS. Notify provider STAT. Save blood bag and tubing (send to blood bank). Draw labs: CBC, BMP, LDH, haptoglobin, DAT, repeat type & screen. Send first-void urine. IV fluids to maintain urine output ≥1 mL/kg/hr to prevent renal tubular injury. Monitor for DIC, shock, renal failure.	Never – never restart this unit or any unit until the error is investigated
TRALI (Transfusion-Related Acute Lung Injury)	During or within 6 hours of the transfusion (most within 1–2 hr)	Acute dyspnea, hypoxia (SpO2 drop), bilateral pulmonary infiltrates on CXR (white-out pattern), fever, often hypotension. No evidence of cardiac cause (no elevated BNP, no JVD, no HTN). Resembles ARDS.	Donor plasma contains anti-HLA or anti-HNA antibodies that activate recipient neutrophils, causing capillary leak in the pulmonary vasculature.	STOP transfusion. Notify provider. Supplemental O2 – many patients require high-flow or mechanical ventilation. Supportive care: no diuresis (unlike TACO). Report to blood bank – the implicated donor is removed from future donations.	Never
TACO (Transfusion-Associated Circulatory Overload)	During or within 12 hours of the transfusion (NHSN); more common in elderly, heart failure, renal failure, small body size	Dyspnea, orthopnea, hypertension (key differentiator from TRALI), tachycardia, elevated JVD, S3 gallop, bilateral crackles, elevated BNP. CXR: bilateral infiltrates with cardiomegaly.	Volume overload – the transfused volume exceeds the patient's circulatory capacity, causing hydrostatic pulmonary edema. It is a fluid overload problem, not an immune problem.	Slow or stop transfusion per provider. Sit patient upright. Administer diuretic (furosemide) as ordered. Supplemental O2. Consider slower transfusion rate for future units in at-risk patients. Premedication with furosemide may be ordered in high-risk patients.	Sometimes – may resume at a slower rate once stabilized, per provider
Anaphylactic	Within seconds to minutes – may occur after <10 mL	Urticaria, pruritus, bronchospasm, stridor, angioedema, hypotension, tachycardia, loss of consciousness. Fever is usually absent.	Severe IgE-type reaction to donor plasma proteins. Anti-IgA antibodies in IgA-deficient patients are the classic textbook cause, but the evidence for that link is weak and most cases have no identified cause (Sandler 2015).	STOP transfusion immediately. Call for help. Epinephrine 0.3–0.5 mg IM (anterolateral thigh). Airway management – prepare for intubation. IV fluids for hypotension. Diphenhydramine, corticosteroids as adjuncts. Future transfusions: washed cellular components (plasma removed), and IgA-deficient products if anti-IgA antibodies are confirmed.	Never
Delayed hemolytic (DHTR)	Usually 3–14 days post-transfusion (NHSN window 24 hours to 28 days)	Unexplained falling hemoglobin, low-grade fever, jaundice, positive DAT. Rarely causes hemoglobinuria or hemodynamic instability.	An anamnestic (recall) immune response – patient was previously sensitized to a red cell antigen (from prior transfusion or pregnancy). Antibody titer was undetectable at crossmatch but rises rapidly after re-exposure.	Notify provider. Obtain repeat type & screen, DAT, CBC, LDH, bilirubin. Usually self-limiting. Future transfusions require antigen-negative units for the implicated antigen.	N/A – occurs after transfusion is complete
Allergic (mild)	During transfusion	Urticaria, pruritus, flushing. No systemic involvement. Vitals stable.	IgE-mediated reaction to plasma proteins in donor blood.	Stop transfusion. Administer diphenhydramine (Benadryl) as ordered. Reassess. If symptoms resolve completely and vitals stable, provider may order restart.	Sometimes – after symptoms fully resolve, per provider order

The “stop the transfusion” universal protocol

When any adverse reaction is suspected – whether mild urticaria or suspected hemolysis – the sequence is always:

Stop the transfusion – close the blood tubing clamp immediately
Disconnect blood tubing at the patient’s IV site – do not flush blood forward into the patient
Keep the IV patent – attach NS and keep the line open for medications and fluids
Notify the provider immediately – describe symptoms and vital signs
Save the blood bag, IV tubing, and any remaining blood – send to the blood bank for analysis; the unit number must be cross-referenced
Obtain urine – look for hemoglobinuria (dark, tea-colored urine indicating intravascular hemolysis)
Draw labs as ordered: CBC, BMP, coagulation panel, LDH, haptoglobin, DAT, repeat type & screen
Document everything – time reaction noted, symptoms, vital signs, interventions, provider notification time

NCLEX critical point: You do not restart the transfusion, call the blood bank, or draw labs first. You stop first, always.

Blood warmer indications

A blood warmer (inline device that heats blood to body temperature during infusion) is indicated in:

Massive transfusion – infusing large volumes of refrigerated blood rapidly causes hypothermia, which worsens coagulopathy and cardiac arrhythmias (the “lethal triad” of trauma: hypothermia, acidosis, coagulopathy)
Cold agglutinin disease – patient’s antibodies agglutinate at low temperatures; warming prevents intra-transfusion hemolysis
Neonates and premature infants – unable to generate sufficient body heat; cold blood causes hypothermia

Never warm blood in a microwave or with hot water. Only use FDA-approved blood warming devices with temperature monitors. Overheating causes hemolysis.

Massive transfusion protocol (MTP)

MTP is activated in life-threatening hemorrhage (typically defined as >10 units PRBCs in 24 hours, or >4 units in 1 hour, or ongoing uncontrolled hemorrhage).

1:1:1 ratio: PRBCs : FFP : Platelets in a 1:1:1 ratio approximates whole blood and limits dilutional coagulopathy. Without adequate FFP and platelets, transfusing only PRBCs dilutes clotting factors and worsens bleeding. In the PROPPR trial (Holcomb 2015), 1:1:1 did not significantly lower 24-hour or 30-day mortality compared with 1:1:2, but more patients achieved hemostasis (86% vs 78%) and fewer died of exsanguination in the first 24 hours (9.2% vs 14.6%).

Permissive hypotension: In trauma patients before surgical hemorrhage control, target systolic BP ~80–90 mmHg (not normal) to prevent clot disruption at injury sites. Once hemorrhage is surgically controlled, normalize BP. This does not apply to traumatic brain injury patients, who need higher perfusion pressure.

Nursing priorities during MTP:

Prepare for rapid infusion – pressure bags or rapid infuser devices
Monitor temperature: blood warmers mandatory
Draw labs every 30–60 minutes: CBC, PT/INR, fibrinogen, ionized calcium
Calcium replacement: citrate (the anticoagulant in stored blood) chelates calcium. With massive transfusion, citrate toxicity causes hypocalcemia → cardiac arrhythmias, decreased cardiac contractility. Monitor ionized calcium and replace as ordered.
Communicate with blood bank continuously – they maintain the ratio supply ahead of bedside need

For hypovolemic shock management, see the shock nursing guide.

Nursing documentation requirements

Document the following for every transfusion:

Pre-transfusion: Bedside verification (both verifiers’ names or bar-code scan record, time), patient consent, baseline vitals, IV access site and gauge, blood product type and unit number, start time
During transfusion: Vital signs at each required interval, patient tolerance, rate adjustments, any symptoms noted
If a reaction occurs: Time of symptom onset, description of symptoms, vital signs at time of reaction, interventions taken (including what was stopped, when, and what NS rate was started), provider notification time, provider name, orders received, unit and tubing disposition, labs drawn
Post-transfusion: End time, total volume infused, final vital signs, patient response

Patients requiring special blood products

Leukoreduced blood: Filtered to remove white blood cells. Standard for most patients now. Reduces febrile non-hemolytic reactions and CMV transmission.

Irradiated blood: Cellular components are irradiated (gamma or x-ray) to inactivate donor T-lymphocytes, preventing transfusion-associated graft-versus-host disease (TA-GvHD). Indications are specific rather than “any immunocompromised patient”. They include stem cell transplant recipients, congenital T-cell immunodeficiency, Hodgkin lymphoma, purine analog therapy such as fludarabine, intrauterine and neonatal exchange transfusions, and components donated by blood relatives or HLA-matched donors (BSH 2020). Routine neonatal top-up transfusions no longer need irradiation. TA-GvHD has >90% mortality.

CMV-seronegative blood: For CMV-negative immunocompromised patients (transplant recipients, HIV patients, neonates of seronegative mothers) – prevents CMV primary infection via transfusion. Leukoreduced blood is considered CMV-safe equivalent.

Washed RBCs: Plasma removed by washing; used after severe or recurrent allergic or anaphylactic reactions to plasma proteins, including confirmed anti-IgA cases.

Patients with anemia may require repeated transfusions and benefit from evaluation for iron deficiency before ongoing transfusion dependence. Patients with thrombocytopenia requiring platelet transfusions should be evaluated for platelet refractoriness (failure of platelet count to rise after transfusion – suggests alloimmunization).

NCLEX tips

The first action when any transfusion reaction is suspected: stop the transfusion. Before calling the provider, before drawing labs, before anything else – close the clamp.
Lactated Ringer’s is absolutely contraindicated with blood products. Calcium in LR chelates citrate anticoagulant → clots form in tubing. Only 0.9% NS is compatible.
Complete each unit within 4 hours. After 4 hours at room temperature, bacterial proliferation risk becomes unacceptable. If a unit cannot be finished in time, stop it and follow blood bank policy for disposal.
Verify at the bedside, with the patient, before starting. Use two-person verification (often two RNs) or one person with bar-code scanning, per facility policy. Verification at the nurses’ station does not count.
TRALI looks like ARDS; TACO looks like pulmonary edema. Useful differentiators: TACO usually brings hypertension, raised JVP and BNP, and improves with diuresis; TRALI more often brings hypotension and fever and does not respond to diuretics. Neither sign is absolute.
Acute hemolytic reaction is the most dangerous – it can occur after just a few milliliters of ABO-incompatible blood. The mechanism is complement activation and intravascular hemolysis, causing renal failure, DIC, and death.
Febrile non-hemolytic reaction is the most common – managed with stopping the transfusion and acetaminophen. Fever can also signal hemolysis or bacterial contamination, so the unit is rarely restarted.
Anaphylaxis and IgA deficiency – NCLEX still links anaphylaxis to IgA-deficient patients with anti-IgA antibodies, but this is an uncommon cause. Anaphylaxis presents within minutes, usually without fever. Stop, give IM epinephrine, and expect washed or IgA-deficient products for future transfusions.
Flank pain + dark urine + fever = acute hemolytic reaction until proven otherwise. Stop immediately.
Platelets at room temperature. Refrigerating platelets causes cold-induced activation and clumping, rendering them non-functional. This is why platelet shelf life is only 5–7 days – room temperature storage increases bacterial contamination risk.
Gauge depends on speed. INS 2024 supports 20–24G for routine transfusion and 14–18G for rapid transfusion. Avoid pressure infusion through small catheters.
Citrate toxicity in massive transfusion – citrate binds ionized calcium → hypocalcemia → arrhythmias, decreased cardiac output, muscle tetany. Monitor ionized calcium and replace proactively.
Irradiated blood for patients at risk of TA-GvHD (stem cell transplant, Hodgkin lymphoma, fludarabine, T-cell immunodeficiency, relative-donor units) – prevents TA-GvHD, which carries >90% mortality. Do not confuse irradiated blood (removes T-lymphocytes) with washed blood (removes plasma).
First 15 minutes: nurse stays at bedside. The most severe reactions occur early and require immediate recognition and intervention.
Document who verified the unit and when – both verifiers’ names, or the bar-code scan, are a regulatory requirement and a safety checkpoint that NCLEX tests directly.

References

AABB. Technical Manual. 22nd ed. Bethesda, MD: AABB; 2026. [Definitive reference for blood product storage, compatibility testing, and transfusion administration standards. Supersedes the 21st edition (2023).]
AABB (Association for the Advancement of Blood & Biotherapies). Standards for Blood Banks and Transfusion Services. 35th ed. AABB; effective 1 April 2026. [Supersedes the 32nd edition (2020).]
U.S. Food and Drug Administration (FDA). Guidance for Industry: Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion. FDA; 2012.
Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion. 2004;44(12):1774–1789. doi:10.1111/j.0041-1132.2004.04347.x
Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012;119(7):1757–1767. [PMID 22117051. Landmark TRALI incidence and donor risk factor study.]
Clifford L, Jia Q, Yadav H, et al. Characterizing the epidemiology of perioperative transfusion-associated circulatory overload. Anesthesiology. 2015;122(1):21–28. [PMID 25611653. TACO characterization study.]
Lieberman L, Maskens C, Cserti-Gazdewich C, et al. A retrospective review of patient factors, transfusion practices, and outcomes in patients with transfusion-associated circulatory overload. Transfus Med Rev. 2013;27(4):206–212. doi:10.1016/j.tmrv.2013.07.002
Delaney M, Wendel S, Bercovitz RS, et al. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016;388(10061):2825–2836. doi:10.1016/S0140-6736(15)01313-6
Roback JD, Grossman BJ, Harris T, Hillyer CD, eds. Technical Manual. 17th ed. Bethesda, MD: AABB; 2011. [Blood warmer indications, massive transfusion protocols, and special product requirements. Superseded by the 22nd edition at reference 1; retained because the cited chapters are the ones this section was originally built from.]
The Joint Commission. Hospital National Patient Safety Goals: NPSG.01.01.01 and NPSG.01.03.01 (eliminate transfusion errors related to patient misidentification: two-person verification or one-person verification with automated identification technology). From 1 January 2026 these requirements sit under National Performance Goal 1, “Right Patient, Right Care”, which consolidated them without adding new requirements.
NCSBN. NCLEX-RN Examination: Test Plan for the National Council Licensure Examination for Registered Nurses. National Council of State Boards of Nursing; effective 1 April 2026. [Pharmacological and parenteral therapies – blood and blood product administration. Supersedes the 2023 test plan.]
Callum JL, Waters JH, Shaz BH, Sloan SR, Murphy MF. The AABB recommendations for the choosing wisely campaign of the American Board of Internal Medicine. Transfusion. 2014;54(9):2344–2352. doi:10.1111/trf.12802
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA. 2015;313(5):471–482. [PMID 25647203. No significant mortality difference at 24 h (12.7% vs 17.0%) or 30 days (22.4% vs 26.1%); more hemostasis and fewer exsanguination deaths with 1:1:1.]
Metcalf RA, Nahirniak S, Guyatt G, et al. Platelet transfusion: 2025 AABB and ICTMG international clinical practice guidelines. JAMA. 2025;334(7):606–617. [Supersedes the 2015 AABB platelet transfusion guideline (Kaufman RM et al, Ann Intern Med. 2015;162(3):205–213).]
Ignatavicius DD, Workman ML, Rebar CR. Medical-Surgical Nursing: Concepts for Interprofessional Collaborative Care. 10th ed. Elsevier; 2021. [Blood transfusion nursing procedures and anemia management reference.]
Carson JL, Stanworth SJ, Guyatt G, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA. 2023;330(19):1892–1902. doi:10.1001/jama.2023.12914
Carson JL, Brooks MM, Hébert PC, et al. Restrictive or liberal transfusion strategy in myocardial infarction and anemia (MINT). N Engl J Med. 2023;389(26):2446–2456. doi:10.1056/NEJMoa2307983 [Liberal threshold below 10 g/dL did not significantly reduce death or recurrent MI at 30 days (RR 1.15, 95% CI 0.99–1.34, P = 0.07).]
Centers for Disease Control and Prevention. National Healthcare Safety Network Biovigilance Component: Hemovigilance Module Surveillance Protocol v3.0. CDC; January 2026. [Case definitions and time windows for FNHTR, AHTR, DHTR, TRALI, TACO, allergic reactions and TA-GvHD.]
Nickel B, Gorski L, Kleidon T, et al. Infusion therapy standards of practice, 9th edition. J Infus Nurs. 2024;47(1S Suppl 1):S1–S285. doi:10.1097/NAN.0000000000000532
Robinson S, Harris A, Atkinson S, et al. The administration of blood components: a British Society for Haematology guideline. Transfus Med. 2018;28(1):3–21. doi:10.1111/tme.12481
Foukaneli T, Kerr P, Bolton-Maggs PHB, et al. Guidelines on the use of irradiated blood components. Br J Haematol. 2020;191(5):704–724. doi:10.1111/bjh.17015
Sandler SG, Eder AF, Goldman M, Winters JL. The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based. Transfusion. 2015;55(1):199–204. doi:10.1111/trf.12796
Bloodworks Northwest. Typical rates, volumes and duration of blood component infusion. Bloodworks Northwest transfusion medicine resources; accessed 18 October 2026.